Eckelman Living Trust Dated February 5, 2014, 10% Owner, Chief Scientific Officer at Inhibrx, Inc. (INBX), sold 80,000 shares at $23.11 ($1.9M) on 2023-01-04, disclosed to the SEC on 2023-01-04.
Open-market sale of $1.9M INBX by 10% Owner, Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.41 | 22,213 | $520K | 27.4% |
| 2 | $23.41 | 22,213 | $520K | 27.4% |
| 3 | $24.36 | 8,598 | $209K | 11.0% |
| 4 | $24.36 | 8,598 | $209K | 11.0% |
| 5 | $25.09 | 2,084 | $52K | 2.8% |
| 6 | $25.09 | 2,084 |
| $52K |
| 2.8% |
| 7 | $23.11 | 4,102 | $95K | 5.0% |
| 8 | $23.11 | 4,102 | $95K | 5.0% |
| 9 | $23.99 | 3,003 | $72K | 3.8% |
| 10 | $23.99 | 3,003 | $72K | 3.8% |
| Total | $23.71 avg | 80,000 | $1.9M | 100% |
| Filing → |
| INBX | SELL | 2021-02-18 | $440K | — | Filing → |